ORIC Pharmaceuticals (ORIC) announced operational highlights for 2025 and anticipated upcoming milestones. Key highlights includes: Announced rinzimetostat Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors; Presented potential best-in-class enozertinib Phase 1b data demonstrating highly competitive systemic and intracranial activity in NSCLC patients with EGFR exon 20 and EGFR PACC mutations; selected Phase 3 monotherapy dose; Raised $244 million from top-tier healthcare specialist funds; Cash and investments of $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout for rinzimetostat Phase 3 study; Expect to report multiple clinical data readouts for rinzimetostat and enozertinib in 2026, ahead of potential initiation of multiple registrational trials
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- 3 Best Biotech Stocks to Buy Today, 1/7/2026, According to Top Analysts
- Oric Pharmaceuticals initiated with an Overweight at Piper Sandler
- Oric Pharmaceuticals Highlights Promising Enozertinib Trial Results
- Oric Pharmaceuticals price target raised to $25 from $19 at Wells Fargo
- Buy Rating for Oric Pharmaceuticals: Enozertinib’s Promising Efficacy and Strategic Value